Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Aphidicolin (HB3690)
Description:DNA replication inhibitor. Useful for cell synchronization
Purity:>98%
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Geldanamycin (HB3311)
Description:Selective Hsp90 inhibitor. Breast cancer stem cell inhibitor.
Purity:>98%